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Duke University, Durham, North CarolinaABSTRACT A previously validated mathematical model of intravascular platelet deposition and tissue factor (TF)-initiated
coagulation under flow is extended and used to assess the influence on thrombin production of the activation of factor XI
(fXI) by thrombin and of the activation of factor IX (fIX) by fXIa. It is found that the importance of the thrombin-fXIa-fIXa feedback
loop to robust thrombin production depends on the concentration of platelets in the blood near the injury. At a near-wall platelet
concentration of ~250,000/mL, typical in vessels in which the shear rate is<200 s1, thrombin activation of fXI makes a significant
difference only at low densities of exposed TF. If the near-wall platelet concentration is significantly higher than this, either
because of a higher systemic platelet count or because of the redistribution of platelets toward the vessel walls at high shear
rates, then thrombin activation of fXI makes a major difference even for relatively high densities of exposed TF. The model
predicts that the effect of a severe fXI deficiency depends on the platelet count, and that fXI becomes more important at high
platelet counts.INTRODUCTIONVascular injury triggers the intertwined processes of platelet
deposition and coagulation. These involve many disparate
physical and chemical interactions competing with or rein-
forcing one another in direct and indirect ways. Correctly
predicting the overall response of the system under specific
conditions is not possible unless these interactions are quan-
titatively accounted for, and for that mathematical models
are a powerful tool. We extend our earlier models (1,2) of
platelet deposition and the tissue-factor (TF) pathway of
coagulation to include a set of reactions that has received
much attention in recent years, activation of factor XI
(fXI) to fXIa by thrombin, and activation of factor IX
(fIX) to fIXa by fXIa. We are interested in how much these
reactions influence thrombin production, and how this influ-
ence depends on blood flow parameters, TF level, and the
near-wall concentration of platelets.
All blood vessels are lined by endothelial cells that nor-
mally work to inhibit platelet deposition and coagulation.
Vascular injury exposes the subendothelium (SE) and clot-
promoting materials in it. Exposed proteins, e.g., collagen
and vonWillebrand factor (vWF), mediate platelet adhesion
to the SE (3). They also activate the bound platelets causing
them to release soluble chemical agonists into the plasma
where these can activate other platelets that do not directly
contact the SE (3). Activated platelets display high-affinity
integrin receptors that serve to anchor interplatelet bridges
formed when a molecule of fibrinogen or vWF binds to
such receptors on two different platelets. By means of these
bridges, a platelet aggregate can be formed on the injured
vascular wall (3).Submitted August 12, 2011, and accepted for publication October 31, 2011.
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0006-3495/12/01/0010/9 $2.00The injury also initiates coagulation by exposing suben-
dothelial TF molecules to the blood (4). The plasma protein
fVIIa binds to the exposed TF to form the powerful suben-
dothelial-bound TF:VIIa enzyme complex (see Fig. 1).
TF:VIIa activates two inactive plasma proteins (zymogens)
into their active enzyme forms, fIX to fIXa and fX to fXa.
On their own in the plasma, fIXa and fXa are weak enzymes.
However, if fIXa and fXa bind to an activated platelet along
with their respective active cofactor molecules, fVIIIa and
fVa, they can form powerful enzyme complexes on the
platelet’s surface (5). The VIIIa:IXa complex (tenase) acti-
vates platelet-bound fX to fXa. The Va:Xa complex (pro-
thrombinase) activates platelet-bound prothrombin into the
enzyme thrombin (also known as fIIa).
Thrombin is the critical coagulation enzyme. It converts
fibrinogen into fibrin monomers that polymerize to form
a gel that mechanically stabilizes platelet aggregates (6).
Thrombin contributes powerfully to the production of
more thrombin. It activates platelets, and thereby increases
the availability of activated platelet surface for the coagula-
tion reactions (3). It activates the cofactor molecules fVIIIa
and fVa required for the VIIIa:IXa and Va:Xa complexes on
the surfaces of activated platelets (7,8). It activates fVII to
fVIIa in plasma and when fVII is bound to TF on the SE
(4). As discussed shortly, it also activates fXI to fXIa.
Fig. 1 shows that fXa activates platelet-bound fVIII and
fV to their active forms fVIIIa and fVa (7,8). This is the
source of these essential cofactor molecules before
thrombin becomes available. The figure also shows the
targets of the principal chemical inhibitors of coagulation:
thrombin, fXa, and fIXa for antithrombin-III (AT-III),
fVIIIa, and fVa for activated protein C (APC), and fXa
and TF:VIIa for tissue factor pathway inhibitor (TFPI)
(9,10). (Note that Fig. 1 does not show the role plateletsdoi: 10.1016/j.bpj.2011.10.048
FIGURE 1 Schematic of coagulation reactions included in our earlier
models. (Dashed magenta arrows) Cellular or chemical activation
processes. (Blue arrows) Chemical transport in the fluid or on a surface.
(Green segments with two arrowheads) Binding and unbinding from
a surface. (Rectangular boxes) Surface-bound species. (Solid black lines
with open arrows) Enzyme action in a forward direction; (dashed black
lines with open arrows) feedback action of enzymes. (Red spheres) Chem-
ical inhibitors.
Factor XIa, Platelets, Coagulation, and Flow 11play in physically inhibiting subendothelial TF:VIIa when
they adhere to the SE and thus cover a portion of it (2,11).
It also does not show reactions involving fXI. These reac-
tions are described below.)
In the contact pathway, fXIIa activates fXI to fXIa, which,
in turn, activates fIX to fIXa (12). This pathway’s relevance
for in vivo hemostasis is unclear because deficiencies of fXII
appear to have no bleeding consequences whereas defi-
ciencies in fXI do (13). The latter vary in severity in ways
that do not correlate directly to the degree of fXI deficiency
(14), but their existence indicates that fXI plays a role in
hemostasis beyond its role in the contact pathway. Because
of this, the role of fXI in the TF pathway has received much
attention in recent years.
Thrombin can activate fXI to fXIa (15,16) and fXIa can
activate fIX to fIXa (17,18) in the plasma and on activated
platelets’ surfaces (13,19). This provides a path to fIXa
production that augments that by TF:VIIa. Factor XIa acti-
vation of fIX increases thrombin production at low [TF]
(13,20,21), it allows continued production of fIXa after
TF:VIIa is inhibited by TFPI or by coverage of the injury
by adherent platelets, and it may provide a burst of thrombin
production leading to thrombin-activatable fibrinolysis
inhibitor activation and consequent inhibition of fibrinolysis
(22). Most in vitro studies of the role of fXI in the TF
pathway were done in static closed systems (no flow) (21–
23) with soluble TF (von dem Borne et al. (22) used
surface-bound TF) and many were done without platelets.
It is difficult to extrapolate meaningful quantitative results
from such studies to an in vivo situation in which productionof thrombin in response to vascular injury involves a
complex biochemical network coordinated with the activa-
tion and deposition of platelets on the vessel wall, and
occurs under flow. Ex vivo studies have shown thrombus
growth is significantly different with fXI and with anti-
body-inhibited-fXI (24), but are not able to provide detailed
quantitative data about the dynamics of the protein concen-
trations that underlie these observations. Even under more-
controlled conditions in vitro, the useful information that
can be extracted from experiments involving coagulation,
platelet deposition, and flow (25) is quite limited.
Our earlier models (1,2) are based on the reaction
network pictured in Fig. 1, a simple description of platelet
deposition, activation, and participation in coagulation reac-
tions, and a simple treatment of flow-mediated transport of
proteins and platelets to or from the vicinity of the injury.
Studies of these models revealed a sharp threshold in
thrombin production in response to different densities of
exposed TF and showed how the threshold [TF] and the
concentration of thrombin produced were modified by
changes in the flow shear rate. They showed that the reduced
thrombin production that occurs with hemophilias A and B
and severe thrombocytopenia are natural consequences of
the kinetics of the reaction system. This work also led us
to propose that as platelets adhere to the SE, they cover
(i.e., pave-over) and so physically inhibit subendothelial
enzymes including TF:VIIa. Our hypothesis was given
experimental support (11), and the predicted threshold and
its dependence on shear rate were seen experimentally
(25). Our studies indicated that, for small injuries, flow-
mediated dilution is a much more potent inhibitor than
TFPI and APC, and highlighted the role of flow and platelet
deposition in establishing the TF threshold. Support for this
prediction comes from comparison between results in
studies of coagulation and platelet deposition under flow
where a TF threshold is seen (25), and others without flow
and platelet deposition, in which no TF threshold is
observed (26).
In Fogelson and Tania (1), platelet deposition shut down
TF:VIIa activity within a few minutes. Only during that
time-window was fIXa produced. For a wide range of
[TF], most of the fIXa and fXa produced by TF:VIIa was
carried away by the flow. A small amount bound to activated
platelets, where the fXa activated fVIII. Only if TF:VIIa
produced sufficient amounts of fIXa and fXa, was enough
VIIIa:IXa complex formed on the adhering platelets’
surfaces to allow substantial fXa production to continue
after platelets covered the SE. We found this to be the key
to whether robust thrombin generation occurred. In this
article, we explore whether a second path to fIXa production
(by fXIa) changes the dynamics seen in Fogelson and Tania
(1) and Kuharsky and Fogelson (2).
Simulations with the new model show that thrombin-
activated fXIa can indeed lead to robust thrombin produc-
tion at low [TF] that, without fXI, would initiate only smallBiophysical Journal 102(1) 10–18
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thrombin production is seen 15–20 min after the initial
injury, rather than after 6–7 min as with high [TF]. More
surprising is the model’s prediction that the concentration
of platelets in the blood near the injury has a strong impact
on how much the availability of fXI influences thrombin
production. If the near-wall concentration of platelets is
high because the bulk platelet count is high, or because, at
high shear rates, the red blood cells’ motion leads to a redis-
tribution of platelets toward the vessel walls (27,28), then
thrombin-catalyzed fXI activation and fXIa-catalyzed fIX
activation are important even at relatively high levels of
exposed TF. The essential reason for this behavior is that
higher platelet counts lead to faster coverage of the SE by
adherent platelets, which causes faster shutdown of TF:VIIa
activity. Hence, the second path to fIXa production becomes
more important. If sensitivity to fXI deficiency depends on
the platelet count, this might help explain the variations in
bleeding tendencies seen with fXI deficiency.METHODS
We assume that the reactions depicted in Fig. 1 occur in a reaction zone
above a small patch of exposed SE (Fig. 2 A). Initially, the reaction zone
does not include platelets and so its height (1–2 mm) is determined by the
height of the boundary layer from which a chemical in the blood flowing
past the injury can reach the SE by diffusion before vanishing downstream.
The height of the reaction zone increases to account for the changing
volume of platelets in the thrombus. Adjacent to the reaction zone, in the
direction perpendicular to the flow, is an endothelial zone (Fig. 2 B) with
height equal to that of the reaction zone and width dependent on the flow
shear rate and protein diffusion coefficients (1). Thrombin can diffuseor
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FIGURE 2 Schematic of (A) reaction zone and (B) endothelial zone. (C)
Schematic of reactions involving fXI or fXIa. (Left) Dimers fXI-fXI and
fXI-fXIa can bind (unbind) to (from) the fXI-specific binding sites, whereas
fXI-fXIa and fXIa-fXIa can bind (unbind) to (from) the fXIa-specific
binding sites. Thrombin can activate fXI to fXIa in solution and on an acti-
vated platelet. Only the dangling-end of a bound dimer can be activated by
thrombin or can activate fIX. (Right) fXI-fXIa and fXIa-fXIa dimers can
activate fIX to fIXa in solution or on an activated platelet.
Biophysical Journal 102(1) 10–18from the reaction zone into the endothelial zone, bind to TM, and produce
APC, which may then diffuse into the reaction zone.
We assume that in the reaction zone, each species is uniformly distrib-
uted and is described by its concentration. Platelets are 1), unactivated,
unattached, and free to move with the fluid, or 2), activated and adherent
to the SE, or 3), activated and bound to other platelets in the thrombus. In
cases 2 and 3, the platelets are stationary. Proteins are distinguished by
their chemical identity and by whether they are in the plasma, bound to
the SE, or bound to an activated platelet. Only those in the plasma move
with the fluid; the others are stationary while they are bound to a surface.
For a protein to get from the SE to a platelet’s surface, it must unbind from
the SE, move through the plasma, and then bind to a receptor on an acti-
vated platelet. While in the plasma, it may be carried downstream by the
flow.
Advective and diffusive transport of each fluid-phase species into or
out of the reaction zone occurs at a rate proportional to 1), the difference
in the species’ concentration in the bulk fluid and in the reaction zone,
and 2), the value of a mass transfer coefficient. The latter depends on the
flow shear rate, the species’ diffusion coefficient, and the size of the injured
patch (2).
Platelets in the bulk fluid are not activated. Platelets can be activated by
contact with the SE, by exposure to thrombin in the plasma, or by contact
with other activated platelets. The last is used as a surrogate for activation
by chemical agonists (ADP and TXA2) released by platelets that the model
does not track.
Surface binding sites for coagulation proteins play a prominent part in the
model. We assume that fVII and fVIIa compete for the TF binding sites on
the SE. Each of the pairs, fIX/fIXa, fX/fXa, fV/fVa, and fVIII/fVIIIa, has
their distinct binding sites on the surfaces of activated platelets for which
the proteins in that pair compete. There are also binding sites specific for
fIXa. In the endothelial zone, thrombin can bind to TM. In a change
from Fogelson and Tania (1) and Kuharsky and Fogelson (2), in which
prothrombin and thrombin were assumed to share platelet binding sites,
here we assume that they have separate sites. This agrees with evidence
available as of this writing that thrombin is released from the platelet
surface upon its activation (29), and that the mechanisms of prothrombin
and thrombin binding to the platelet are different (see the Supporting
Material).
Our assumptions about protein interactions, other than the new ones
involving fXI and fXIa, follow. Further discussion of them including cita-
tions to the literature can be found in Kuharsky and Fogelson (2):
1. fVII and fVIIa can bind to subendothelial TF. fXa can activate fVII in
plasma and when fVII is bound to TF. fXa can bind to TF:VII directly
from the plasma.
2. fIX and fX can be activated by the TF:VIIa complex on the SE. They
compete to bind to TF:VIIa directly from plasma. fX can also be acti-
vated by the platelet-bound VIIIa:IXa complex.
3. Prothrombin can be activated to thrombin by the platelet-bound Va:Xa
complex.
4. fVand fVIII can be activated by thrombin in plasma and by thrombin and
fXa on the surfaces of activated platelets.
5. The chemical inhibitors are AT-III, APC, and TFPI. Because [AT-III] is
high, we assume it acts in a first-order manner to permanently inactivate
plasma fIXa, fXa, and thrombin. APC is produced in the endothelial
zone by the TM-thrombin complex. It can bind to platelet-bound fVa
and fVIIIa to permanently inactivate them. TFPI in the plasma must first
bind to fXa, and then the TFPI:fXa complex must bind to the TF:VIIa
complex to inhibit it.
6. When a platelet adheres to the SE, it physically blocks the activity of the
TF:VIIa complexes on the patch of SE to which it has adhered.
To this model, we have added reactions in which thrombin activates fXI
to fXIa, and ones in which fXIa activates fIX to fIXa. We assume that each
of these reactions can take place in plasma or on an activated platelet’s
surface. We also have added reactions describing fXI and fXIa binding to
and unbinding from the surfaces of activated platelets.
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Factor XIa, Platelets, Coagulation, and Flow 13That fXI circulates as a dimer may be essential for some of its functions
in coagulation (30,31). Because of the slow rate of activation of fXI by
thrombin, dimers in which only one of the halves has been activated are
common (32,33). We track three versions of the dimer in the plasma, which
we denote fXI-fXI, fXI-fXIa, and fXIa-fXIa, with no, one, or both halves
activated, respectively. The half-activated dimer is an active enzyme (33)
and we assume it activates fIX at the same rate as that for each half of a fully
activated dimer. We assume that there are 1500 binding sites for fXI and
250 distinct ones for fXIa on each activated platelet (34,35), and that the
fXI dimers bind to these sites as depicted in Fig. 2 C, a scenario similar
to that suggested in Gailani et al. (30). We denote the four types of the
bound dimer as Plt-fXI-fXI, Plt-fXI-fXIa, Plt-fXIa-fXI, and Plt-fXIa-
fXIa. In the first two, an unactivated half-dimer is bound to a fXI-specific
site; in the latter two, an activated half-dimer is bound to a fXIa-specific
site. We assume that the dimer half that is bound to a platelet is not available
for other reactions. Only the dangling ends of the dimers are available for
reactions with thrombin or fIX. We use kcat ¼ 1.3 (10)4 s1 and KM ¼
50 nM (15) for activation of fXI by thrombin in plasma and on platelets;
kcat ¼ 0.21 s1and KM ¼ 0.2 mM for fXIa activation of fIX (30) in plasma
and on platelets (36); KD ¼ 10 nM for fXI binding with platelets (37); and
KD ¼ 1.7 nM for fXIa binding with platelets (35).
In the model, the concentration of each protein satisfies an ordinary
differential equation (ODE) that includes terms for each reaction in which
that species is involved and a term describing the species’ transport if it is in
the fluid. A complete description of the model is given in the Supporting
Material. Here, we use two of the new equations to illustrate the types of
reactions that the model includes:
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FIGURE 3 [fIIa] at 10 min and 20 min versus [TF] with normal [fXI]
(solid) and no fXI (dashed) with near-wall platelet count 250,000/mL and
shear rate 100 s1.dt
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tion z9) to form a transient complex on the way to activating fIX to fIXa (D).
It is produced by thrombin’s activation of fXI-fXI (E), binds with thrombin
(e2) on the way to being fully activated by it (F), and is inactivated by AT-III
(G). Plt-fXI-fXIa is formed when fXI-fXIa binds to platelet binding sites for
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The model’s ODEs are solved using DLSODE (38). For each simulation,
we specify the plasma concentrations of all zymogens and enzymes (typi-
cally only [fVIIa] is nonzero) and platelets, the rate constants for all reac-
tions, the numbers of each type of binding site on an activated platelet, the
dimensions of the injury, the flow velocity near the injured wall, the diffu-
sion coefficients for all fluid-phase species, and the density of exposed TF.
The simulation outputs are the concentration of every zymogen and enzyme
within the reaction and endothelial zones every 1 s from initiation of the
injury until the completion of the simulation, as well as the concentrations
of unactivated platelets and platelets attached either directly to the SE or to
other platelets.RESULTS
Uniform platelet concentration
We performed a series of simulations distinguished only by
the [TF] exposed in the injury. The model equations were
solved for 20 min and we recorded all concentrations at
10 min and 20 min post injury for each [TF]. We did this
for normal [fXI] (NfXI ¼ 30 nM) and with no fXI. Fig. 3
shows the total thrombin concentration [fIIa] (the concentra-
tion of all species that include the active thrombin enzyme)
at these times for a simulation with a flow shear rate of
100 s1. For each curve, there is a small interval of [TF]
over which [fIIa] increases sharply from values (%10 pM)
at which thrombin has little physiological effect to values
(R10 nM) at which it has a profound effect. We refer to
the center of this interval as the threshold; it is ~3 fmol/cm2
at 20 min and just under 5 fmol/cm2 at 10 min. For shear
rate 50 s1, the results (not shown) are very similar with
a maximum [fIIa] ~4% higher and the threshold shifted
slightly to the left. For shear rate 500 s1 (not shown), the
curves are again similar, but the upstroke in the curves isBiophysical Journal 102(1) 10–18
14 Fogelson et al.shifted to the right by 2–3 fmol/cm2 and the maximum [fIIa]
is ~4% less than at shear rate 100 s1.
From Fig. 3, we see that without fXI, [fIIa] has a threshold
dependence on [TF], and that the threshold [TF] varies
somewhat depending on the flow shear rate, consistent
with results in Kuharsky and Fogelson (2). The threshold
level is lower if one considers [fIIa] at 20 min rather than
at 10 min. With NfXI, for sufficiently low [TF] there is no
significant change in [fIIa] at 10 and 20 min, and in these
cases, [fIIa] is subpicomolar. For high [TF], a high [fIIa]
develops by 10 min and remains high at 20 min, and the
fXI reactions have little effect on [fIIa] achieved. There is
an interval of [TF] for which the fXI reactions lead to
a substantial increase in [fIIa] at 20 min. No similar interval
of [TF] exists for which a significant increase occurs in
[fIIa] at 10 min, so the effect of fXI appears late.
To understand why it takes >10 min before significant
additional amounts of thrombin are produced with NfXI,
we look at the timecourse of several species’ concentrations
in simulations, one with NfXI and one without fXI, per-
formed with [TF] ¼ 3.5 fmol/cm2, shear rate 100 s1, and
near-wall platelet count of 250,000/mL. In both cases,
[fIIa] builds slowly, reaching 1 nM only after >800 s. In
Fig. 4 A, we see that with NfXI, the growing [fIIa] is accom-0 200 400 600 800 1000 1200
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FIGURE 4 [TF]¼ 3.5 fmol/cm2, shear rate 100 s1, and near-wall platelet cou
and no fXI (dashed).
Biophysical Journal 102(1) 10–18panied by a slow rise in the concentration of the platelet-
bound fXI-thrombin complex, paralleled with delays, by
a slow rise in [Plt-fXI-fXIa] (other fXIa species also form
but at much lower concentrations) and in the concentration
of the complex of Plt-fXI-fXIa with Plt-fIX. [Plt-fXI-fXIa]
rises slowly because [fIIa] does and because the kcat for
thrombin-catalyzed activation of fXIa is small. Starting at
~850 s, the rates of increase of [Plt-fXI-fXI:fIIa], [Plt-fXI-
fXIa], and [Plt-fXI-fXIa:fIX] (see Fig. 4 B) successively
increase at a rapid rate as thrombin binds to Plt-fXI-fXI
and half-activates it, and then the resulting Plt-fXI-fXIa
dimer binds to Plt-fIX on the way to activating it. Starting
at ~500 s, the effect of Plt-fXI-fXIa becomes increasingly
apparent, as the decline in [Plt-fIXa] slows and then reverses
with NfXI, while it continues to drop without fXI (Fig. 4 B).
The upswing in [Plt-fIXa] and the increase of [Plt-fVIIIa]
(with and without fXI) lead to a rapid increase in the
concentrations of the tenase complex and the complex of te-
nase and Plt-fX (Fig. 4 C) starting at ~900 s. This is followed
in quick succession (Fig. 4 D) by rapid increases in [Plt-
fXa], [Plt-Va:Xa], and [fIIa] so that from ~1000 s on, there
is substantially more thrombin with fXI than without.
It is noteworthy that, up until the time that the effect
of fXIa really takes hold, there is actually a little more0 200 400 600 800 1000 1200
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Factor XIa, Platelets, Coagulation, and Flow 15thrombin (and platelet-bound fVa, fVIIIa, tenase, and pro-
thrombinase) without fXI than with it. This happens because
fXI competes with fV and fVIII for thrombin and so slows
their activation by it. Fig. 4 shows that a significant fraction
of the total thrombin is, in fact, bound to fXI on platelets.Platelet near-wall excess
For the simulations just reported, we assumed that the
concentration of platelets supplied to the reaction zone by
transport was 250,000/mL. This is reasonable if the platelets
are distributed uniformly across the vessel lumen, which is
the case for shear rates <~200 s1. At higher shear rates,
the platelet concentration is enhanced within a few microns
of the vessel walls and is reduced over the central part of the
lumen. The platelet near-wall excess (NWE) concentration
can be 2–8-fold higher than at the vessel’s center (27,28).
A reasonable way to account for the platelet NWE in the
simulations is to supply nonactivated platelets to the reac-
tion zone at a higher concentration that is based on experi-
mental observations (27,28).
The effect of the platelet NWE on thrombin production in
simulations without fXI is shown in Fig. 5 A. [fIIa] is signif-
icantly less when the near-wall platelet count is 750,000/mL,
three times the normal uniform count. This reduction can be
traced to the fact that the SE is covered by platelets much
faster at the higher platelet count. Hence, production of
fIXa and fXa by TF:VIIa drops off more rapidly. The forma-
tion of Plt-VIIIa:IXa requires the simultaneous presence of
Plt-fVIIIa (activated initially by fXa) and fIXa (1), and these
are both substantially reduced with the higher platelet count.
Consequently, there is less and slower formation of pro-
thrombinase and less production of thrombin.
Adding fXI provides another pathway to fIXa production.
Fig. 5 B shows thrombin production in simulations with
various [TF], shear rate 500 s1, and with near-wall platelet
count 750,000/mL. [fIIa] at 10 min is changed little by the
fXI reactions. There is a gradual increase in [fIIa] at
10 min with [TF]; [fIIa] ¼ 1 nM occurs only for [TF] above0 200 400 600 800 1000 1200
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FIGURE 5 [TF] ¼ 15 fmol/cm2, shear rate 500 s1. (A) No fXI and near-wa
VIIIa:IXa] and [fIIa] versus time. (B and C) Near-wall platelet count 750,000.
no fXI (dashed). (C) [Plt-VIIIa:IXa], [Plt-Va:Xa], and [fIIa] versus time with NfX
covered 99% of the SE.~17 fmol/cm2, and no threshold dependence is exhibited.
Without fXI, [fIIa] at 20 min again increases only gradually
with [TF] and no threshold is apparent. In contrast,
with NfXI, [fIIa] is >100-fold higher for [TF] of 12–
13 fmol/cm2 than at 10 fmol/cm2. Thus, the presence of
fXI restores the threshold nature of thrombin production
and leads to substantially more thrombin for above-
threshold [TF] than for below-threshold [TF], and for the
same [TF] in the absence of fXI. Fig. 5 C shows how [Plt-
VIIIa:IXa], [Plt-Va:Xa], and [fIIa] vary in time for shear
rate 500 s1, [TF] ¼ 15 fmol/cm2, and platelet count
750,000/mL with and without fXI. We see that the effect
of fXI on the final amount of thrombin produced can be
strongly influenced by the concentration of platelets.
Fig. 6 shows further evidence that the platelet count influ-
ences the sensitivity of the coagulation system to variations
in [fXI]. For shear rates 100 s1 and 500 s1, simulations
were carried out with several different platelet counts and
[fXI] equal to 100%, 10%, and 1% of its normal plasma
level. For each set of parameter values, [fIIa] at 20 min is
plotted against [TF]. Fig. 6 A shows four sets of plots for
platelet counts 125,000–500,000/mL. For each [fXI], the
threshold level of TF increases with platelet count, because
the faster coverage of the SE at higher platelet count neces-
sitates higher [TF] to produce the same thrombin concentra-
tions. For each platelet count, there is little difference
between the curves for NfXI and 10% NfXI, but for 1%
NfXI the reduction in thrombin production grows steadily
with the platelet count. For platelet count 125,000/mL, there
is a narrow range of [TF] for which thrombin production for
10% NfXI is approximately twice that for 1% NfXI. For
platelet count 500,000/mL, there is a broader range of
[TF] for which thrombin production is substantially more
(by close to 100-fold in some cases) for 10% NfXI than
for 1% NfXI. It is also useful to consider for fixed [TF],
say 3 fmol/cm2, what the interplay between platelet count
and [fXI] implies about thrombin production. For this
[TF], reduction of [fXI] to 10% or 1% of normal has little
effect for platelet count 125,000/mL, a major impact for0 15 20
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16 Fogelson et al.250,000/mL, and very little effect for 375,000/mL. Without
knowing the platelet count, the effect of a particular defi-
ciency of fXI cannot be predicted.
For a shear rate 500 s1 at which a platelet NWE occurs,
we looked at higher platelet counts from 250,000/mL to
1,000,000/mL. Fig. 6 B shows that the curves shift to the
right as the near-wall platelet count increases. Further, the
width of the interval of [TF] for which the thrombin produc-
tion at 1% NfXI is much less than at 10%NfXI grows signif-
icantly with increasing platelet count. At higher platelet
counts, there are intervals of [TF], albeit narrow ones, for
which a 10% NfXI leads to substantially less thrombin
production than for NfXI.DISCUSSION
Using a mathematical model of intravascular clotting in
which coagulation occurs in tandem with platelet deposition
and under flow, we explored the effect of thrombin-activated
fXIa on thrombin production during TF-initiated coagula-
tion. Our main result is the prediction that the sensitivity
of thrombin production to the plasma [fXI] depends strongly
not only on the level of exposed TF but also on the concen-
tration of platelets. A high concentration of platelets in the
blood within a few microns of the vessel wall increases
the importance of fXI in the production of thrombin.
Based primarily on in vitro experiments without flow or
platelets, it is believed that thrombin-activated fXIa plays
a significant role in thrombin production only at low [TF].
The results depicted in Fig. 3 are consistent with this view
and suggest that, even accounting for platelet deposition
and flow, this view is correct. Further explorations show
that the story may be more interesting.
Because platelet deposition physically inhibits its
activity, TF:VIIa remains active for a length of time that
depends on the near-wall platelet count and on the flow
speed near the injury. Because high shear rates lead toBiophysical Journal 102(1) 10–18higher near-wall platelet counts (28) and thus to faster
platelet deposition, thrombin production that relies solely
on TF:VIIa to generate fIXa is much reduced at higher shear
rates (500 s1 and above) even at high [TF] (15 fmol/cm2).
As seen in Fig. 5, simply increasing the near-wall platelet
count from 250,000 to 750,000/mL caused a significant
drop in [fIIa] at both 10 min and 20 min. In another simula-
tion with the higher platelet count, but with NfXI, [fIIa] at
20 min was substantially higher. The presence of the fXI
reactions neutralized the effect of the threefold-higher
platelet count on [fIIa] at 20 min.
Fluid-phase fXIa is inhibited by potent plasma proteins
(including C1-inhibitor) and by protease-nexin 2 released
from activated platelets (32), whereas platelet-bound fXIa
is protected from these inhibitors (39,40). These inhibitors
are not included in our model, so it may overpredict fXIa
concentrations in the fluid. This should have little impact
on the results because flow-mediated removal of plasma-
phase species from the reaction zone is itself a potent regu-
lator of local concentrations. The dominant fXIa species,
by far, in the simulations is Plt-fXI-fXIa, which is the
only form of fXIa in the model that at no time during its
formation requires the enzyme to be free in the plasma.
Some people with fXI deficiency bleed excessively when
they suffer trauma to tissues with high fibrinolytic activity
(14,41). A rationale for this is that fXI is required for high
levels of thrombin production after clot formation (i.e.,
a thrombin burst), which, in turn, is required to activate
the fibrinolytic inhibitor thrombin-activatable fibrinolysis
inhibitor-a (13,22). Although our model includes neither
fibrin formation nor fibrinolysis, it does make predictions
about the conditions under which a burst of thrombin
production will occur. Our results suggest that the bleeding
that fXI-deficient people experience in lysis-prone tissues
may be more severe if their platelet count is also elevated.
This counterintuitive result arises because of the platelets’
dual role; in addition to providing the surfaces on which
Factor XIa, Platelets, Coagulation, and Flow 17thrombin production occurs, the platelets also play an anti-
coagulant role by covering the TF exposed on the vascular
wall.
Below-normal [fXI] protects against venous thrombosis
(42) and some forms of arterial thrombosis (41), whereas
above-normal [fXI] increases the risk of these diseases
(43,44). Arterial thrombosis is primarily associated with
rupture or erosion of atheroma and the consequent exposure
of TF and other clot-promoting materials. Because our
model indicates an important role for fXI under high shear
conditions even for relatively high [TF], reduced fXI may
lead to lower thrombin production in these situations.
How venous thrombosis is initiated is much less clear; it
may involve the adhesion of TF-bearing microparticles to
activated endothelial cells (45). It seems reasonable that
the level of TF expression in these situations will often be
less than with overt vascular wall trauma. Also unclear is
whether the concept of adherent platelets paving-over the
damaged vascular wall is directly relevant, but the observa-
tion that platelet attachment to vWF released by activated
endothelial cells may be an essential component of venous
thrombosis (46) suggests that it may be. In any case, the
model’s prediction that fXI deficiency reduces thrombin
generation for low TF exposures under venous flow condi-
tions and normal platelet counts is consistent with a protec-
tive effect. In our simulations, above-normal [fXI] does not
increase thrombin production. This suggests that mecha-
nisms other than those under study here are the reasons
for increased risk of thrombosis with elevated fXI.
Our predictions can be tested in a number of ways: One
could do studies in an in vitro flow chamber with a surface
coated with collagen and TF (as in Okorie et al. (25)), using
normal and fXI deficient blood, and controlling the platelet
count by adding washed platelets to the perfusate. Experi-
ments could also be done using fXI knockout mice (47).
With clinical data tabulating [fXI], platelet count, and
bleeding behavior, one could determine whether patients
with fXI deficiency and platelet count in the low-normal
range bled less than those with fXI deficiency and platelet
count in the high-normal range. Such studies could validate
the predictions made with the model and establish whether
platelet count provides an independent, clinically relevant
risk factor for bleeding in fXI-deficient people.
In the model presented, we assume that each chemical
or platelet species is well mixed in the reaction zone. We
treat flow and transport in a simple way and allow for little
influence of the deposited platelets on the delivery of
proteins and platelets to the reaction zone. These are reason-
able approximations for small spatial domains and small
thrombi. For larger injuries and for larger thrombi that
grow substantially into the vessel lumen, and to account
more fully for interaction between growing thrombi and
the flow, a more complex spatial-temporal model is
required. For a larger thrombus, the relative importance of
fIXa generated by TF:VIIa and that generated by platelet-bound fXIa may shift toward the latter because of the greater
number of platelets in the thrombus. We have made signif-
icant progress in developing a model that can address such
issues (48).
The results of this article suggest a general principle that
the higher the bulk platelet count, the more important
thrombin-activated fXIa is in further thrombin production.
In vessels where the shear rate is sufficiently high to
cause a high near-wall concentration of platelets to develop,
this feedback mechanism seems to be critical to a strong
response to vascular injury, even at relatively high TF
exposures.SUPPORTING MATERIAL
Additional methodology with definition of terms, 76 supporting equations,
and eight tables are available at http://www.biophysj.org/biophysj/
supplemental/S0006-3495(11)01314-2.
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